# A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants

> **NCT03501277** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 72 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Alogliptin
- **DRUG:** Pioglitazone
- **DRUG:** SYR-322-4833 BL

## Key facts

- **NCT ID:** NCT03501277
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-26
- **Primary completion:** 2018-07-11
- **Final completion:** 2018-07-11
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2019-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03501277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03501277, "A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03501277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*